重磅研究抢先看，TNBC、HR+乳腺癌前沿5分钟速览！| 2024 SABCS

*仅供医学专业人士阅读参考

直击2024 SABCS，见证乳腺癌治疗革新

整理 | lily

2024年12月10日-13日，第47届圣安东尼奥乳腺癌研讨会（SABCS）将在美国圣安东尼奥隆重举行。作为乳腺癌研究领域中规模最大、最具盛名的科学聚会之一，SABCS大会集结了近一年来乳腺癌领域的最新研究成果、临床实践经验、治疗进展和技术创新等内容。

日前，大会公布了摘要标题。医学界特整理部分LBA Oral Session、General Session、Rapid Fire Session的口头报告研究，分类为HR+/HER2-乳腺癌、三阴性乳腺癌（TNBC），以供读者参考。

HR+/HER2-乳腺癌

摘要号：LB1-03

Primary results of the randomised Phase III trial comparing first-line ET plus palbociclib vs standard mono-chemotherapy in women with high risk HER2-/HR+ metastatic breast cancer and indication for chemotherapy - PADMA study.

一线内分泌治疗（ET）联合哌柏西利vs标准单药化疗用于具备化疗指征的高危HR+/HER2-转移性女性乳腺癌患者中疗效的随机III期试验——PADMA研究主要结果。

讲者：Sibylle Loibl, German Cooperative Group, Neu-Isenburg, Germany

摘要号：LB1-04

Efficacy and safety of trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) by pace of disease progression on prior endocrine-based therapy: additional analysis from DESTINY-Breast06.

根据既往以ET为基础的方案治疗的疾病进展速度，德曲妥珠单抗（T-DXd）vs医生选择的化疗（TPC）疗效和安全性：DESTINY-Breast06的事后分析。

讲者：Aditya Bardia, UCLA David Geffen School of Medicine, Los Angeles, California

摘要号：LB1-05

ROSC (Neo) adjuvant nab-PAC weekly vs sb-PAC q2w, followed by EC q2w, in genomically or clinically high-risk HR+/HER- early breast cancer according to ET-response: final survival results from the WSG ADAPT-HR+/HER2- chemotherapy-trial.

根据内分泌治疗疗效，ROSC（新）辅助白蛋白紫杉醇每周1次vs 溶剂型紫杉醇每两周1次，序贯EC化疗每两周1次，用于遗传性或临床高危HR+/HER-早期乳腺癌：WSG ADAPT-HR+/HER2-化疗试验的最终生存结果。

讲者：Sherko Kuemmel, German Medical Institute, Limassol, Germany

摘要号：LB1-06

Primary results of SOLTI VALENTINE: neoadjuvant randomized phase II trial of HER3-DXd alone or in combination with letrozole for high-risk hormone receptor positive (HR+)/HER2-negative (neg) early breast cancer (EBC).

SOLTI VALENTINE研究的主要结果：一项旨在评估HER3-DXd± 来曲唑治疗高危HR+/HER2-早期乳腺癌（EBC）的新辅助随机II期试验。

讲者：Mafalda Oliveira, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

摘要号：GS1-01

Imlunestrant, an Oral Selective Estrogen Receptor Degrader (SERD), as Monotherapy and Combined with Abemaciclib, for Patients w/ ER+, HER2- Advanced Breast Cancer (ABC), Pretreated w/ Endocrine Therapy (ET): Results of the Phase 3 EMBER-3 trial.

Imlunestrant，一种口服选择性雌激素受体降解剂（SERD），联合或不联合阿贝西利用于接受过ET的ER+/HER2-晚期乳腺癌（ABC）患者：III期EMBER-3试验结果。

讲者：Komal Jhaveri, Memorial Sloan Kettering Cancer Center, New York, New York

摘要号：GS2-01

Exclusive endocrine therapy or radiation therapy in women aged 70+ years with luminal-like early breast cancer (EUROPA): preplanned interim analysis of a randomized phase 3 trial.

个性化ET或放射治疗用于70岁以上luminal型早期乳腺癌女性患者（EUROPA）：一项随机III期试验的预设中期分析。

讲者：Icro Meattini, University of Florence, Florence, Italy

摘要号：GS3-03

Impact of Anthracyclines in High Genomic Risk Node-Negative HR+/HER2- Breast Cancer.

蒽环类药物在高基因组风险淋巴结阴性HR+/HER2-乳腺癌中的影响。

讲者：Nan Chen, University of Chicago Medicine, Chicago, Illinois

摘要号：GS3-09

Multimodal integration of real world clinical and genomic data for the prediction of CDK4/6 inhibitors outcomes in patients with HR+/HER2- metastatic breast cancer.

多模态整合真实世界临床和基因组数据，以预测HR+/HER2-转移性乳腺癌患者中CDK4/6抑制剂的疗效。

讲者：Enrico Moiso, Memorial Sloan Kettering Cancer Center, New York, New York

摘要号：RF3-01

TBCRC 056: A phase II study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: Results from the ER+/HER2- cohort.

II期TBCRC 056研究的ER+/HER2-队列的结果：一项新辅助尼拉帕利联合dostarlimab治疗BRCA或PALB2突变乳腺癌患者。

讲者：Erica Mayer, Dana-Farber Cancer Institute, Boston, Massachusetts

TNBC

摘要号：LB1-07

Exploratory Biomarker Analysis of the Phase 3 KEYNOTE-522 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage TNBC.

早期TNBC患者接受新辅助帕博利珠单抗±化疗后，帕博利珠单抗或安慰剂辅助治疗的III期KEYNOTE-522研究探索性生物标志物分析。

讲者：Joyce O’Shaughnessy, Baylor-Sammons Cancer Center, Dallas, Texas

摘要号：GS3-05

NSABP B-59/GBG-96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo followed by adjuvant atezolizumab or placebo in patients with Stage II and III triple-negative breast cancer.

NSABP B-59/GBG-96-GeparDouze研究：一项评估化疗联合阿替利珠单抗/安慰剂新辅助治疗，随后阿替利珠单抗/安慰剂辅助治疗II/III期三TNBC疗效的随机、双盲、3期临床试验。

讲者：Charles Geyer, University of Pittsburgh, Pittsburgh, Pennsylvania

摘要号：GS3-06

Neoadjuvant camrelizumab plus chemotherapy (chemo) for early or locally advanced triple-negative breast cancer (TNBC): a randomized, double-blind, phase 3 trial.

卡瑞利珠单抗联合化疗（chemo）新辅助治疗早期或局部晚期TNBC：一项随机、双盲、III期试验。

讲者：邵志敏教授，复旦大学附属肿瘤医院

摘要号：RF3-02

Efficacy of adjuvant avelumab by PD-L1, tumor infiltrating lymphocytes and residual cancer burden in high-risk triple negative breast cancer: secondary and exploratory endpoints of the phase III A-BRAVE trial.

根据PD-L1、肿瘤浸润性淋巴细胞和残留癌症负担评估辅助avelumab治疗高风险TNBC的疗效：III期A-BRAVE试验的次要和探索性终点。

讲者：Maria Vittoria Dieci, University of Padua, Padua, Italy

摘要号：RF3-03

Nivolumab + Ipilimumab (NIVO+IPI) compared to capecitabine for triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy – Final results of BreastImmune-03, a multicenter randomized open-label phase II trial.

纳武利尤单抗+伊匹木单抗（NIVO+IPI）vs卡培他滨用于新辅助化疗后有残留病灶的TNBC患者的疗效——多中心、随机、开放标签、II期BreastImmune-03研究的最终结果。

讲者：Olivier Trédan, Centre Lèon Bèrard, Lyon, France

精彩资讯等你来

责任编辑：Sheep

*医学界力求其发表内容专业、可靠，但不对内容的准确性做出承诺；请相关各方在采用或以此作为决策依据时另行核查。